ABT-869 another TKI / VEGF - 27 mo stability in ASPS

[Fictional]

Hi everybody,

ABT-869 is a TKI / VEGF inhibitor which at least in one patient with ASPS was reported to have prolonged stability (27 months) with minimal side effects. The full-text report is here - you can search for "alveolar soft part sarcoma". It's not clear whether the person eventually progressed after 27 months, or they only started 27 months ago. The drug is in phase II.

http://www.pubmedcentral.nih.gov/articl ... =pmcentrez